With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.832710-65-3,2,8-Diazaspiro[4.5]decan-1-one hydrochloride,as a common compound, the synthetic route is as follows.
2,8-Diazaspiro[4.5]decan-1 -one hydrogen chloride (200 mg, 1.049 mmol) was dissolved in a mixture of triethylamine (0.439 ml, 3.15 mmol) and dichloromethane (10 ml), and 2-bromo-5-(trifluoromethyl)benzenesulfonyl chloride (407 mg, 1 .259 mmol) was added. The reaction mixture was stirred for 16 h and the reaction mixture was concentrated in vacuo. The resulting yellow solid 8-{[2-bromo-5- (trifluoromethyl)phenyl]sulfonyl}-2,8-diazaspiro[4.5]decan-1 -one (825 mg, impure) was used in the next reaction without further purification. MS ES+ve m/z 443 (M+H). 8-{[2-bromo-5-(trifluoromethyl)phenyl]sulfonyl}-2,8-diazaspiro[4.5]decan-1 -one (825 mg, impure) and potassium carbonate (217 mg, 1.574 mmol) was suspended in 1 ,4- dioxane (10 ml_). Trimethylboroxine (0.219 ml_, 1.574 mmol) and Pd(PPh3)4 (121 mg, 0.105 mmol) were then added and the reaction mixture was heated to 100 C. After 20 h, the reaction was cooled, filtered through a hydrophobic frit, and concentrated in vacuo. The resulting residue was purified by silica column chromatography on SP4 (gradient elution: 0 – 20% MeOH – DCM). The resulting brown residue was further purified on MDAP twice to give 8-{[2-methyl-5-(trifluoromethyl)phenyl]sulfonyl}-2,8- diazaspiro[4.5]decan-1 -one (41 mg, 0.107 mmol) as a white solid. 1 H N MR (400 MHz, DMSO-de) delta ppm 1.39 – 1.49 (m, 2 H) 1.58 – 1 .70 (m, 2 H) 1 .89 (t, J=6.80 Hz, 2 H) 2.65 (s, 3 H) 2.84 – 2.95 (m, 2 H) 3.13 (t, J=6.80 Hz, 2 H) 3.54 (ddd, J=12.63, 4.08, 3.95 Hz, 2 H) 7.63 (s, 1 H) 7.74 (d, J=7.95 Hz, 1 H) 7.98 (dd, J=8.03, 1 .40 Hz, 1 H) 8.03 (d, J=1 .21 Hz, 1 H). MS ES+ve m/z 377 (M+H).
832710-65-3 2,8-Diazaspiro[4.5]decan-1-one hydrochloride 42614558, apiperidines compound, is more and more widely used in various.
Reference£º
Patent; CONVERGENCE PHARMACEUTICALS LIMITED; GLEAVE, Robert James; HACHISU, Shuji; PAGE, Lee William; WO2011/141729; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem